<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39309757</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2329-0501</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>12</Day></PubDate></JournalIssue><Title>Molecular therapy. Methods &amp; clinical development</Title><ISOAbbreviation>Mol Ther Methods Clin Dev</ISOAbbreviation></Journal><ArticleTitle>Lipid nanoparticle encapsulation of a Delta spike-CD40L DNA vaccine improves effectiveness against Omicron challenge in Syrian hamsters.</ArticleTitle><Pagination><StartPage>101325</StartPage><MedlinePgn>101325</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101325</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.omtm.2024.101325</ELocationID><Abstract><AbstractText>The effectiveness of mRNA vaccines largely depends on their lipid nanoparticle (LNP) component. Herein, we investigate the effectiveness of DLin-KC2-DMA (KC2) and SM-102-based LNPs for the intramuscular delivery of a plasmid encoding B.1.617.2 (Delta) spike fused with CD40 ligand. LNP encapsulation of this CD40L-adjuvanted DNA vaccine with either LNP formulation drastically enhanced antibody responses, enabling neutralization of heterologous Omicron variants. The DNA-LNP formulations provided excellent protection from homologous challenge, reducing viral replication, and preventing histopathological changes in the pulmonary tissues. Moreover, the DNA-LNP vaccines maintained a high level of protection against heterologous Omicron BA.5 challenge despite a reduced neutralizing response. In addition, we observed that DNA-LNP vaccination led to the pulmonary downregulation of interferon signaling, interleukin-12 signaling, and macrophage response pathways following SARS-CoV-2 challenge, shedding some light on the mechanisms underlying the prevention of pulmonary injury. These results highlight the potential combination of molecular adjuvants with LNP-based vaccine delivery to induce greater and broader immune responses capable of preventing inflammatory damage and protecting against emerging variants. These findings could be informative for the future design of both DNA and mRNA vaccines.</AbstractText><CopyrightInformation>Crown Copyright © 2024 Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tamming</LastName><ForeName>Levi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON K1A 0K9, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duque</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Human Health Therapeutics Research Center, National Research Council of Canada, Ottawa, ON K1A 0R6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Anh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Human Health Therapeutics Research Center, National Research Council of Canada, Ottawa, ON K1A 0R6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lansdell</LastName><ForeName>Casey</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON K1A 0K9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frahm</LastName><ForeName>Grant</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON K1A 0K9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jianguo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON K1A 0K9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fekete</LastName><ForeName>Emily E F</ForeName><Initials>EEF</Initials><AffiliationInfo><Affiliation>Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON K1A 0K9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Creskey</LastName><ForeName>Marybeth</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON K1A 0K9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thulasi Raman</LastName><ForeName>Sathya N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON K1A 0K9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laryea</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON K1A 0K9, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wanyue</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON K1A 0K9, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfeifle</LastName><ForeName>Annabelle</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON K1A 0K9, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gravel</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON K1A 0K9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stalker</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON K1A 0K9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashem</LastName><ForeName>Anwar M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21859, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah 21859, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wangxue</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Human Health Therapeutics Research Center, National Research Council of Canada, Ottawa, ON K1A 0R6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stuible</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Human Health Therapeutics Research Center, National Research Council of Canada, Ottawa, ON K1A 0R6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durocher</LastName><ForeName>Yves</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Human Health Therapeutics Research Center, National Research Council of Canada, Ottawa, ON K1A 0R6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Safronetz</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Jingxin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lisheng</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sauve</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON K1A 0K9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosu-Myles</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON K1A 0K9, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON K1A 0K9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnston</LastName><ForeName>Michael J W</ForeName><Initials>MJW</Initials><AffiliationInfo><Affiliation>Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON K1A 0K9, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, Carleton University, Ottawa, ON K1S 5B6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xuguang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON K1A 0K9, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Ther Methods Clin Dev</MedlineTA><NlmUniqueID>101624857</NlmUniqueID><ISSNLinking>2329-0501</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CD40 ligand</Keyword><Keyword MajorTopicYN="N">DNA vaccine</Keyword><Keyword MajorTopicYN="N">Omicron variants</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antibody</Keyword><Keyword MajorTopicYN="N">lipid nanoparticle</Keyword><Keyword MajorTopicYN="N">nucleic acid</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>7</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>7</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>5</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39309757</ArticleId><ArticleId IdType="pmc">PMC11416279</ArticleId><ArticleId IdType="doi">10.1016/j.omtm.2024.101325</ArticleId><ArticleId IdType="pii">S2329-0501(24)00141-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Moghadas S.M., Vilches T.N., Zhang K., Wells C.R., Shoukat A., Singer B.H., Meyers L.A., Neuzil K.M., Langley J.M., Fitzpatrick M.C., Galvani A.P. The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States. Clin. Infect. Dis. 2021;73:2257–2264. doi: 10.1093/CID/CIAB079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/CID/CIAB079</ArticleId><ArticleId IdType="pmc">PMC7929033</ArticleId><ArticleId IdType="pubmed">33515252</ArticleId></ArticleIdList></Reference><Reference><Citation>Feikin D.R., Higdon M.M., Abu-Raddad L.J., Andrews N., Araos R., Goldberg Y., Groome M.J., Huppert A., O’Brien K.L., Smith P.G., et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399:924–944. doi: 10.1016/S0140-6736(22)00152-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00152-0</ArticleId><ArticleId IdType="pmc">PMC8863502</ArticleId><ArticleId IdType="pubmed">35202601</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobrovitz N., Ware H., Ma X., Li Z., Hosseini R., Cao C., Selemon A., Whelan M., Premji Z., Issa H., et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect. Dis. 2023;23:556–567. doi: 10.1016/S1473-3099(22)00801-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00801-5</ArticleId><ArticleId IdType="pmc">PMC10014083</ArticleId><ArticleId IdType="pubmed">36681084</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson O.J., Barnsley G., Toor J., Hogan A.B., Winskill P., Ghani A.C. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect. Dis. 2022;22:1293–1302. doi: 10.1016/S1473-3099(22)00320-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00320-6</ArticleId><ArticleId IdType="pmc">PMC9225255</ArticleId><ArticleId IdType="pubmed">35753318</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMOA2035389/SUPPL_FILE/NEJMOA2035389_DATA-SHARING.PDF.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMOA2035389/SUPPL_FILE/NEJMOA2035389_DATA-SHARING.PDF</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMOA2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMOA2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias S., Harper C., Vrbicky K., Walsh S.R., Essink B., Brosz A., McGhee N., Tomassini J.E., Chen X., Chang Y., et al. A Bivalent Omicron-Containing Booster Vaccine against Covid-19. N. Engl. J. Med. 2022;387:1279–1291. doi: 10.1056/NEJMOA2208343/SUPPL_FILE/NEJMOA2208343_DATA-SHARING.PDF.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMOA2208343/SUPPL_FILE/NEJMOA2208343_DATA-SHARING.PDF</ArticleId><ArticleId IdType="pmc">PMC9511634</ArticleId><ArticleId IdType="pubmed">36112399</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas S.J., Moreira E.D., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Polack F.P., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N. Engl. J. Med. 2021;385:1761–1773. doi: 10.1056/NEJMOA2110345/SUPPL_FILE/NEJMOA2110345_DATA-SHARING.PDF.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMOA2110345/SUPPL_FILE/NEJMOA2110345_DATA-SHARING.PDF</ArticleId><ArticleId IdType="pmc">PMC8461570</ArticleId><ArticleId IdType="pubmed">34525277</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou X., Zaks T., Langer R., Dong Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 2021;6:1078–1094. doi: 10.1038/s41578-021-00358-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41578-021-00358-0</ArticleId><ArticleId IdType="pmc">PMC8353930</ArticleId><ArticleId IdType="pubmed">34394960</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson B., Geetha K.M. Lipid nanoparticles in the development of mRNA vaccines for COVID-19. J. Drug Deliv. Sci. Technol. 2022;74:103553. doi: 10.1016/J.JDDST.2022.103553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JDDST.2022.103553</ArticleId><ArticleId IdType="pmc">PMC9238147</ArticleId><ArticleId IdType="pubmed">35783677</ArticleId></ArticleIdList></Reference><Reference><Citation>Blakney A.K., McKay P.F., Yus B.I., Aldon Y., Shattock R.J. Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA. Gene Ther. 2019;26:363–372. doi: 10.1038/s41434-019-0095-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41434-019-0095-2</ArticleId><ArticleId IdType="pmc">PMC6760535</ArticleId><ArticleId IdType="pubmed">31300730</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Eygeris Y., Gupta M., Sahay G. Self-assembled mRNA vaccines. Adv. Drug Deliv. Rev. 2021;170:83–112. doi: 10.1016/J.ADDR.2020.12.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.ADDR.2020.12.014</ArticleId><ArticleId IdType="pmc">PMC7837307</ArticleId><ArticleId IdType="pubmed">33400957</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucker E.M., Karmali P.P., Vega J., Kwilas S.A., Wu H., Joselyn M., Ballantyne J., Sampey D., Mukthavaram R., Sullivan E., et al. Lipid Nanoparticle Formulation Increases Efficiency of DNA-Vectored Vaccines/Immunoprophylaxis in Animals Including Transchromosomic Bovines. Sci. Rep. 2020;101:8764–8813. doi: 10.1038/s41598-020-65059-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-65059-0</ArticleId><ArticleId IdType="pmc">PMC7260227</ArticleId><ArticleId IdType="pubmed">32472093</ArticleId></ArticleIdList></Reference><Reference><Citation>Connors J., Joyner D., Mege N.J., Cusimano G.M., Bell M.R., Marcy J., Taramangalam B., Kim K.M., Lin P.J.C., Tam Y.K., et al. Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals. Commun. Biol. 2023;61:1–13. doi: 10.1038/s42003-023-04555-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-023-04555-1</ArticleId><ArticleId IdType="pmc">PMC9936473</ArticleId><ArticleId IdType="pubmed">36805684</ArticleId></ArticleIdList></Reference><Reference><Citation>Ndeupen S., Qin Z., Jacobsen S., Bouteau A., Estanbouli H., Igyártó B.Z. The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience. 2021;24:103479. doi: 10.1016/J.ISCI.2021.103479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.ISCI.2021.103479</ArticleId><ArticleId IdType="pmc">PMC8604799</ArticleId><ArticleId IdType="pubmed">34841223</ArticleId></ArticleIdList></Reference><Reference><Citation>Alameh M.G., Tombácz I., Bettini E., Lederer K., Sittplangkoon C., Wilmore J.R., Gaudette B.T., Soliman O.Y., Pine M., Hicks P., et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity. 2021;54:2877–2892.e7. doi: 10.1016/j.immuni.2021.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.11.001</ArticleId><ArticleId IdType="pmc">PMC8566475</ArticleId><ArticleId IdType="pubmed">34852217</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y., Jeong M., Park J., Jung H., Lee H. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Exp. Mol. Med. 2023:2085–2096. doi: 10.1038/s12276-023-01086-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-023-01086-x</ArticleId><ArticleId IdType="pmc">PMC10618257</ArticleId><ArticleId IdType="pubmed">37779140</ArticleId></ArticleIdList></Reference><Reference><Citation>Kafetzis K.N., Papalamprou N., McNulty E., Thong K.X., Sato Y., Mironov A., Purohit A., Welsby P.J., Harashima H., Yu-Wai-Man C., Tagalakis A.D. The Effect of Cryoprotectants and Storage Conditions on the Transfection Efficiency, Stability, and Safety of Lipid-Based Nanoparticles for mRNA and DNA Delivery. Adv. Healthc. Mater. 2023;12:2203022. doi: 10.1002/ADHM.202203022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ADHM.202203022</ArticleId><ArticleId IdType="pubmed">36906918</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M.A. A Comparison of Plasmid DNA and mRNA as Vaccine Technologies. Vaccines. 2019;7:37. doi: 10.3390/VACCINES7020037.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/VACCINES7020037</ArticleId><ArticleId IdType="pmc">PMC6631684</ArticleId><ArticleId IdType="pubmed">31022829</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulroney T.E., Pöyry T., Puc Y.-, Carlos J., Rust M., Harvey R.F., Kalmar L., Horner E., Booth L., Ferreira A.P., et al. N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting. Nature. 2023;2023:189–194. doi: 10.1038/s41586-023-06800-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06800-3</ArticleId><ArticleId IdType="pmc">PMC10764286</ArticleId><ArticleId IdType="pubmed">38057663</ArticleId></ArticleIdList></Reference><Reference><Citation>Melo A.R.da S., de Macêdo L.S., Invenção M.d.C.V., Invenção M.da C.V., da Gama M.A.T.M., Andrêssa I., Silva A.J.D., Batista M.V.d.A., Freitas A.C.d., Cristiane M.L., et al. Third-Generation Vaccines: Features of Nucleic Acid Vaccines and Strategies to Improve Their Efficiency. Genes. 2022;13:2287. doi: 10.3390/GENES13122287.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/GENES13122287</ArticleId><ArticleId IdType="pmc">PMC9777941</ArticleId><ArticleId IdType="pubmed">36553554</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamming L.A., Duque D., Tran A., Zhang W., Pfeifle A., Laryea E., Wu J., Raman S.N.T., Gravel C., Russell M.S., et al. DNA Based Vaccine Expressing SARS-CoV-2 Spike-CD40L Fusion Protein Confers Protection Against Challenge in a Syrian Hamster Model. Front. Immunol. 2021;12:785349. doi: 10.3389/FIMMU.2021.785349.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2021.785349</ArticleId><ArticleId IdType="pmc">PMC8789660</ArticleId><ArticleId IdType="pubmed">35095861</ArticleId></ArticleIdList></Reference><Reference><Citation>Elgueta R., Benson M.J., De Vries V.C., Wasiuk A., Guo Y., Noelle R.J. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 2009;229:152–172. doi: 10.1111/J.1600-065X.2009.00782.X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/J.1600-065X.2009.00782.X</ArticleId><ArticleId IdType="pmc">PMC3826168</ArticleId><ArticleId IdType="pubmed">19426221</ArticleId></ArticleIdList></Reference><Reference><Citation>Harzandi N., Aghababa H., Khoramabadi N., Tabaraie T. Efficient Immunization of BALB/c Mice against Pathogenic Brucella melitensis and B. ovis: Comparing Cell-Mediated and Protective Immune Responses Elicited by pCDNA3.1 and pVAX1 DNA Vaccines Coding for Omp31 of Brucella melitensis. Iran. J. Biotechnol. 2021;19:40–47. doi: 10.30498/IJB.2021.2618.</Citation><ArticleIdList><ArticleId IdType="doi">10.30498/IJB.2021.2618</ArticleId><ArticleId IdType="pmc">PMC8217529</ArticleId><ArticleId IdType="pubmed">34179193</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan L., Zhu H., Zhou M., Ma J., Chen R., Chen Y., Chen L., Wu K., Cai M., Hong J., et al. Gender associates with both susceptibility to infection and pathogenesis of SARS-CoV-2 in Syrian hamster. Signal Transduct. Target. Ther. 2021;6:136–138. doi: 10.1038/s41392-021-00552-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00552-0</ArticleId><ArticleId IdType="pmc">PMC8009924</ArticleId><ArticleId IdType="pubmed">33790236</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellan M., Zamperin G., Franzoni G., Foiani G., Zorzan M., Drzewnioková P., Mancin M., Brian I., Bortolami A., Pagliari M., et al. Host Response of Syrian Hamster to SARS-CoV-2 Infection including Differences with Humans and between Sexes. Viruses. 2023;15:428. doi: 10.3390/V15020428/S1.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/V15020428/S1</ArticleId><ArticleId IdType="pmc">PMC9960357</ArticleId><ArticleId IdType="pubmed">36851642</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassett K.J., Benenato K.E., Jacquinet E., Lee A., Woods A., Yuzhakov O., Himansu S., Deterling J., Geilich B.M., Ketova T., et al. Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines. Mol. Ther. Nucleic Acids. 2019;15:1–11. doi: 10.1016/j.omtn.2019.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2019.01.013</ArticleId><ArticleId IdType="pmc">PMC6383180</ArticleId><ArticleId IdType="pubmed">30785039</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Pfeifle A., Lansdell C., Frahm G., Cecillon J., Tamming L., Gravel C., Gao J., Thulasi Raman S.N., Wang L., et al. The Expression Kinetics and Immunogenicity of Lipid Nanoparticles Delivering Plasmid DNA and mRNA in Mice. Vaccines. 2023;11:1580. doi: 10.3390/VACCINES11101580/S1.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/VACCINES11101580/S1</ArticleId><ArticleId IdType="pmc">PMC10610642</ArticleId><ArticleId IdType="pubmed">37896985</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito A., Irie T., Suzuki R., Maemura T., Nasser H., Uriu K., Kosugi Y., Shirakawa K., Sadamasu K., Kimura I., et al. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature. 2022;602:300–306. doi: 10.1038/s41586-021-04266-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04266-9</ArticleId><ArticleId IdType="pmc">PMC8828475</ArticleId><ArticleId IdType="pubmed">34823256</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D., Veyer D., Baidaliuk A., Staropoli I., Guivel-Benhassine F., Rajah M.M., Planchais C., Porrot F., Robillard N., Puech J., et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596:276–280. doi: 10.1038/s41586-021-03777-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03777-9</ArticleId><ArticleId IdType="pubmed">34237773</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey W.T., Carabelli A.M., Jackson B., Gupta R.K., Thomson E.C., Harrison E.M., Ludden C., Reeve R., Rambaut A., et al. COVID-19 Genomics UK COG-UK Consortium SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 2021;19:409–424. doi: 10.1038/s41579-021-00573-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00573-0</ArticleId><ArticleId IdType="pmc">PMC8167834</ArticleId><ArticleId IdType="pubmed">34075212</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudriavtsev A.V., Vakhrusheva A.V., Novoseletsky V.N., Bozdaganyan M.E., Shaitan K.V., Kirpichnikov M.P., Sokolova O.S. Immune Escape Associated with RBD Omicron Mutations and SARS-CoV-2 Evolution Dynamics. Viruses. 2022;14:1603. doi: 10.3390/V14081603.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/V14081603</ArticleId><ArticleId IdType="pmc">PMC9394476</ArticleId><ArticleId IdType="pubmed">35893668</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty C., Sharma A.R., Bhattacharya M., Lee S.S. A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations. Front. Immunol. 2022;13:801522. doi: 10.3389/FIMMU.2022.801522/BIBTEX.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2022.801522/BIBTEX</ArticleId><ArticleId IdType="pmc">PMC8863680</ArticleId><ArticleId IdType="pubmed">35222380</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang R., Ye Z.W., Ong C.P., Qin Z., Xie Y., Fan Y., Tang K., Poon V.K.M., Chan C.C.S., Yang X., et al. The spike receptor-binding motif G496S substitution determines the replication fitness of SARS-CoV-2 Omicron sublineage. Emerg. Microbes Infect. 2022;11:2093–2101. doi: 10.1080/22221751.2022.2111977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2111977</ArticleId><ArticleId IdType="pmc">PMC9448440</ArticleId><ArticleId IdType="pubmed">35943779</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu P., Evans J.P., Faraone J.N., Zheng Y.M., Carlin C., Anghelina M., Stevens P., Fernandez S., Jones D., Lozanski G., et al. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. Cell Host Microbe. 2023;31:9–17.e3. doi: 10.1016/j.chom.2022.11.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2022.11.012</ArticleId><ArticleId IdType="pmc">PMC9678813</ArticleId><ArticleId IdType="pubmed">36476380</ArticleId></ArticleIdList></Reference><Reference><Citation>Uraki R., Ito M., Furusawa Y., Yamayoshi S., Iwatsuki-Horimoto K., Adachi E., Saito M., Koga M., Tsutsumi T., Yamamoto S., et al. Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB. Lancet Infect. Dis. 2023;23:30–32. doi: 10.1016/S1473-3099(22)00816-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00816-7</ArticleId><ArticleId IdType="pmc">PMC9729000</ArticleId><ArticleId IdType="pubmed">36495917</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu P., Faraone J.N., Evans J.P., Zheng Y.M., Carlin C., Anghelina M., Stevens P., Fernandez S., Jones D., Panchal A.R., et al. Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants. Cell Rep. 2023;42:112443. doi: 10.1016/J.CELREP.2023.112443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CELREP.2023.112443</ArticleId><ArticleId IdType="pmc">PMC10279473</ArticleId><ArticleId IdType="pubmed">37104089</ArticleId></ArticleIdList></Reference><Reference><Citation>Ao D., He X., Hong W., Wei X. The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants. MedComm. 2023;4:e239. doi: 10.1002/MCO2.239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/MCO2.239</ArticleId><ArticleId IdType="pmc">PMC10015854</ArticleId><ArticleId IdType="pubmed">36938325</ArticleId></ArticleIdList></Reference><Reference><Citation>Willett B.J., Grove J., MacLean O.A., Wilkie C., De Lorenzo G., Furnon W., Cantoni D., Scott S., Logan N., Ashraf S., et al. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nat. Microbiol. 2022;7:1161–1179. doi: 10.1038/s41564-022-01143-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-022-01143-7</ArticleId><ArticleId IdType="pmc">PMC9352574</ArticleId><ArticleId IdType="pubmed">35798890</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J., Liu Z., Zhang G., Xu W., Xing L., Lu L., Wang Q., Jiang S. Development of variant-proof severe acute respiratory syndrome coronavirus 2, pan-sarbecovirus, and pan-β-coronavirus vaccines. J. Med. Virol. 2023;95:e28172. doi: 10.1002/JMV.28172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JMV.28172</ArticleId><ArticleId IdType="pmc">PMC9538210</ArticleId><ArticleId IdType="pubmed">36161303</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W., Zhou J.Q., Horvath S.C., Schmitz A.J., Sturtz A.J., Lei T., Liu Z., Kalaidina E., Thapa M., Alsoussi W.B., et al. Germinal centre-driven maturation of B cell response to mRNA vaccination. Nature. 2022;604:141–145. doi: 10.1038/s41586-022-04527-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04527-1</ArticleId><ArticleId IdType="pmc">PMC9204750</ArticleId><ArticleId IdType="pubmed">35168246</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue T., Shinnakasu R., Kawai C., Yamamoto H., Sakakibara S., Ono C., Itoh Y., Terooatea T., Yamashita K., Okamoto T., et al. Antibody feedback contributes to facilitating the development of Omicron-reactive memory B cells in SARS-CoV-2 mRNA vaccinees. J. Exp. Med. 2023;220:e20221786. doi: 10.1084/JEM.20221786/213745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/JEM.20221786/213745</ArticleId><ArticleId IdType="pmc">PMC9750191</ArticleId><ArticleId IdType="pubmed">36512034</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenart K., Hellgren F., Ols S., Yan X., Cagigi A., Cerveira R.A., Winge I., Hanczak J., Mueller S.O., Jasny E., et al. A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses. Mol. Ther. Methods Clin. Dev. 2022;27:309–323. doi: 10.1016/j.omtm.2022.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtm.2022.10.001</ArticleId><ArticleId IdType="pmc">PMC9535876</ArticleId><ArticleId IdType="pubmed">36217434</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwa S., Lai L., Gangadhara S., Siddiqui M., Pillai V.B., Labranche C., Yu T., Moss B., Montefiori D.C., Robinson H.L., et al. CD40L-Adjuvanted DNA/Modified Vaccinia Virus Ankara Simian Immunodeficiency Virus SIV239 Vaccine Enhances SIV-Specific Humoral and Cellular Immunity and Improves Protection against a Heterologous SIVE660 Mucosal Challenge. J. Virol. 2014;88:9579–9589. doi: 10.1128/JVI.00975-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00975-14</ArticleId><ArticleId IdType="pmc">PMC4136340</ArticleId><ArticleId IdType="pubmed">24920805</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashem A.M., Gravel C., Chen Z., Yi Y., Tocchi M., Jaentschke B., Fan X., Li C., Rosu-Myles M., Pereboev A., et al. CD40 Ligand Preferentially Modulates Immune Response and Enhances Protection against Influenza Virus. J. Immunol. 2014;193:722–734. doi: 10.4049/JIMMUNOL.1300093.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/JIMMUNOL.1300093</ArticleId><ArticleId IdType="pubmed">24928989</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau J.J., Cheng S.M.S., Leung K., Lee C.K., Hachim A., Tsang L.C.H., Yam K.W.H., Chaothai S., Kwan K.K.H., Chai Z.Y.H., et al. Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population. Nat. Med. 2023;29:348–357. doi: 10.1038/s41591-023-02219-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02219-5</ArticleId><ArticleId IdType="pmc">PMC9941049</ArticleId><ArticleId IdType="pubmed">36652990</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner J.S., O’Halloran J.A., Kalaidina E., Kim W., Schmitz A.J., Zhou J.Q., Lei T., Thapa M., Chen R.E., Case J.B., et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature. 2021;596:109–113. doi: 10.1038/s41586-021-03738-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03738-2</ArticleId><ArticleId IdType="pmc">PMC8935394</ArticleId><ArticleId IdType="pubmed">34182569</ArticleId></ArticleIdList></Reference><Reference><Citation>Aid M., Busman-Sahay K., Vidal S.J., Maliga Z., Bondoc S., Starke C., Terry M., Jacobson C.A., Wrijil L., Ducat S., et al. Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques. Cell. 2020;183:1354–1366.e13. doi: 10.1016/j.cell.2020.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.005</ArticleId><ArticleId IdType="pmc">PMC7546181</ArticleId><ArticleId IdType="pubmed">33065030</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendisch D., Dietrich O., Mari T., von Stillfried S., Ibarra I.L., Mittermaier M., Mache C., Chua R.L., Knoll R., Timm S., et al. SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell. 2021;184:6243–6261.e27. doi: 10.1016/J.CELL.2021.11.033/ATTACHMENT/F61754D9-B3D7-4A0E-9D20-2067CC9C519F/MMC6.XLSX.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CELL.2021.11.033/ATTACHMENT/F61754D9-B3D7-4A0E-9D20-2067CC9C519F/MMC6.XLSX</ArticleId><ArticleId IdType="pmc">PMC8626230</ArticleId><ArticleId IdType="pubmed">34914922</ArticleId></ArticleIdList></Reference><Reference><Citation>Nouailles G., Wyler E., Pennitz P., Postmus D., Vladimirova D., Kazmierski J., Pott F., Dietert K., Muelleder M., Farztdinov V., et al. Temporal omics analysis in Syrian hamsters unravel cellular effector responses to moderate COVID-19. Nat. Commun. 2021;12:4869. doi: 10.1038/S41467-021-25030-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41467-021-25030-7</ArticleId><ArticleId IdType="pmc">PMC8357947</ArticleId><ArticleId IdType="pubmed">34381043</ArticleId></ArticleIdList></Reference><Reference><Citation>Suresh V., Mohanty V., Avula K., Ghosh A., Singh B., Reddy R.K., Parida D., Suryawanshi A.R., Raghav S.K., Chattopadhyay S., et al. Quantitative proteomics of hamster lung tissues infected with SARS-CoV-2 reveal host factors having implication in the disease pathogenesis and severity. FASEB J. 2021;35:e21713. doi: 10.1096/FJ.202100431R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/FJ.202100431R</ArticleId><ArticleId IdType="pmc">PMC8206718</ArticleId><ArticleId IdType="pubmed">34105201</ArticleId></ArticleIdList></Reference><Reference><Citation>Aid M., Vidal S.J., Piedra-Mora C., Ducat S., Chan C.N., Bondoc S., Colarusso A., Starke C.E., Nekorchuk M., Busman-Sahay K., et al. Ad26.COV2.S prevents upregulation of SARS-CoV-2 induced pathways of inflammation and thrombosis in hamsters and rhesus macaques. PLoS Pathog. 2022;18:e1009990. doi: 10.1371/JOURNAL.PPAT.1009990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/JOURNAL.PPAT.1009990</ArticleId><ArticleId IdType="pmc">PMC9020736</ArticleId><ArticleId IdType="pubmed">35395058</ArticleId></ArticleIdList></Reference><Reference><Citation>Waickman A.T., Victor K., Newell K., Li T., Friberg H., Foulds K.E., Roederer M., Bolton D.L., Currier J.R., Seder R. mRNA-1273 vaccination protects against SARS-CoV-2–elicited lung inflammation in nonhuman primates. JCI Insight. 2022;7:e160039. doi: 10.1172/JCI.INSIGHT.160039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI.INSIGHT.160039</ArticleId><ArticleId IdType="pmc">PMC9310526</ArticleId><ArticleId IdType="pubmed">35653196</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer M., Wang Y., Edwards D., Smith G.R., Rubenstein A.B., Ramanathan P., Mire C.E., Pietzsch C., Chen X., Ge Y., et al. Attenuated activation of pulmonary immune cells in mRNA-1273–vaccinated hamsters after SARS-CoV-2 infection. J. Clin. Invest. 2021;131:e148036. doi: 10.1172/JCI148036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI148036</ArticleId><ArticleId IdType="pmc">PMC8516449</ArticleId><ArticleId IdType="pubmed">34449440</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifle A., Thulasi Raman S.N., Lansdell C., Zhang W., Tamming L., Cecillon J., Laryea E., Patel D., Wu J., Gravel C., et al. DNA lipid nanoparticle vaccine targeting outer surface protein C affords protection against homologous Borrelia burgdorferi needle challenge in mice. Front. Immunol. 2023;14:1020134. doi: 10.3389/FIMMU.2023.1020134/BIBTEX.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2023.1020134/BIBTEX</ArticleId><ArticleId IdType="pmc">PMC10060826</ArticleId><ArticleId IdType="pubmed">37006299</ArticleId></ArticleIdList></Reference><Reference><Citation>Algarni A., Pilkington E.H., Suys E.J.A., Al-Wassiti H., Pouton C.W., Truong N.P. In vivo delivery of plasmid DNA by lipid nanoparticles: the influence of ionizable cationic lipids on organ-selective gene expression. Biomater. Sci. 2022;10:2940–2952. doi: 10.1039/D2BM00168C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D2BM00168C</ArticleId><ArticleId IdType="pubmed">35475455</ArticleId></ArticleIdList></Reference><Reference><Citation>Guimaraes L.C., Carvalho P.A., Júnior S., Aluotto S.R., Ferreira H.A.S., Braga A.C.S., Oliveira de, Camilo L., Figueiredo M.M., Shepherd S., et al. Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models. Nat. Commun. 2024;15:1–19. doi: 10.1038/s41467-024-44830-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-44830-1</ArticleId><ArticleId IdType="pmc">PMC10796936</ArticleId><ArticleId IdType="pubmed">38238326</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao H.-C., Shen K.-Y., Huang M.S., Yang C.H., Chiu F.F., Chiang C.Y., Chai K.M., Huang W.C., Ho H.M., Chen Y.H., et al. Lipid nanoparticle-encapsulated DNA vaccine robustly induce superior immune responses to the mRNA vaccine in Syrian hamsters. Mol. Ther. Methods Clin. Dev. 2024;32:101169. doi: 10.1016/J.OMTM.2023.101169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.OMTM.2023.101169</ArticleId><ArticleId IdType="pmc">PMC10767207</ArticleId><ArticleId IdType="pubmed">38187094</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O., Graham B.S., McLellan J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263. doi: 10.1126/SCIENCE.ABB2507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/SCIENCE.ABB2507</ArticleId><ArticleId IdType="pmc">PMC7164637</ArticleId><ArticleId IdType="pubmed">32075877</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuible M., Gervais C., Lord-Dufour S., Perret S., L'Abbé D., Abbé D., Schrag J., St-Laurent G., Durocher Y. Rapid, high-yield production of full-length SARS-CoV-2 spike ectodomain by transient gene expression in CHO cells. J. Biotechnol. 2021;326:21–27. doi: 10.1016/J.JBIOTEC.2020.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JBIOTEC.2020.12.005</ArticleId><ArticleId IdType="pmc">PMC7720734</ArticleId><ArticleId IdType="pubmed">33301853</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark F.C., Akache B., Deschatelets L., Tran A., Stuible M., Durocher Y., McCluskie M.J., Agbayani G., Dudani R., Harrison B.A., et al. Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters. Sci. Rep. 2022;12:9772–9811. doi: 10.1038/s41598-022-13819-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-13819-5</ArticleId><ArticleId IdType="pmc">PMC9191540</ArticleId><ArticleId IdType="pubmed">35697917</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie J., Li Q., Wu J., Zhao C., Hao H., Liu H., Zhang L., Nie L., Qin H., Wang M., et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat. Protoc. 2020;15:3699–3715. doi: 10.1038/s41596-020-0394-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-020-0394-5</ArticleId><ArticleId IdType="pubmed">32978602</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed L.J., Muench H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 1938;27:493–497. doi: 10.1093/OXFORDJOURNALS.AJE.A118408/2/27-3-493.PDF.GIF.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/OXFORDJOURNALS.AJE.A118408/2/27-3-493.PDF.GIF</ArticleId></ArticleIdList></Reference><Reference><Citation>Wölfel R., Corman V.M., Guggemos W., Seilmaier M., Zange S., Müller M.A., Niemeyer D., Jones T.C., Vollmar P., Rothe C., et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;2020:465–469. doi: 10.1038/s41586-020-2196-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2196-x</ArticleId><ArticleId IdType="pubmed">32235945</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris G., Holbein B.E., Zhou H., Xu H.H., Chen W. Potential mechanisms of mucin-enhanced acinetobacter baumannii virulence in the mouse model of intraperitoneal infection. Infect. Immun. 2019;87 doi: 10.1128/IAI.00591-19/SUPPL_FILE/IAI.00591-19-S0001.PDF.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.00591-19/SUPPL_FILE/IAI.00591-19-S0001.PDF</ArticleId><ArticleId IdType="pmc">PMC6803341</ArticleId><ArticleId IdType="pubmed">31405959</ArticleId></ArticleIdList></Reference><Reference><Citation>Lien C.E., Lin Y.J., Chen C., Lian W.C., Kuo T.Y., Campbell J.D., Traquina P., Lin M.Y., Liu L.T.C., Chuang Y.S., et al. CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge. Sci. Rep. 2021;11:8761–8767. doi: 10.1038/s41598-021-88283-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-88283-8</ArticleId><ArticleId IdType="pmc">PMC8062487</ArticleId><ArticleId IdType="pubmed">33888840</ArticleId></ArticleIdList></Reference><Reference><Citation>Creskey M., Li L., Ning Z., Fekete E.E.F., Mayne J., Walker K., Ampaw A., Ben R., Zhang X., Figeys D. An economic and robust TMT labeling approach for high throughput proteomic and metaproteomic analysis. Proteomics. 2023;23:2200116. doi: 10.1002/PMIC.202200116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/PMIC.202200116</ArticleId><ArticleId IdType="pubmed">36528842</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang T., Choi M., Tzouros M., Golling S., Pandya N.J., Banfai B., Dunkley T., Vitek O. MSstatsTMT: Statistical Detection of Differentially Abundant Proteins in Experiments with Isobaric Labeling and Multiple Mixtures. Mol. Cell. Proteomics. 2020;19:1706–1723. doi: 10.1074/mcp.RA120.002105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.RA120.002105</ArticleId><ArticleId IdType="pmc">PMC8015007</ArticleId><ArticleId IdType="pubmed">32680918</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>